The National Comprehensive Cancer Network has concluded its 2021 Patient Advocacy Summit, which focused on expanding precision medicine in order to improve cancer outcomes, featuring discussions on federal and local policies to broaden genetic/genomic testing access.
As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments. Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...
